NVCR News and Press, NovoCure Limited From 07/22/19

Introduction I first introduced the story of NovoCure ( NVCR ) in November 2017 when shares were trading below $20. Today, shares of NovoCure trade near $70. I was interested in NovoCure's new modality to treat cancer: the use of tumor treating fields that work to upset broken &am...

The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NASDAQ: NVCR) today announced 10 oral presentations and a special session on Tumor Treating Fields at the 41st International Engineering in Medicine and Biolog...

Novocure (NASDAQ: NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. Additional details on the fee schedule amount and pricing methodology are available on the CMS website . The announcement by C...

Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective Se...

Zai Lab is a Chinese biotech company mainly focuses on oncology. It licenses in innovative drugs and medical devices from various US partners and tries to get CFDA approval and commercialization in China. Examples of such pipelines are niraparib from GSK (previously Tesaro), Optune from Novocu...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended...

Establishment Labs Holdings (NASDAQ: ESTA ) initiated with Outperform rating and $29 (38% upside) price target at Wells Fargo. More news on: Establishment Labs Holdings Inc., NovoCure Limited, Avid Bioservices, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

The German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published Novocure's (NASDAQ: NVCR ) rapid report concluding that, based on a review of its EF-14 phase 3 trial, patients with newly diagnosed glioblastoma (GBM) lived longer when treated with Optune in addit...

National reimbursement decision for Optune® in Germany anticipated in 2020 Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s...